
Tesamorelin
Modified GHRH peptide studied for growth-hormone patterns and abdominal fat research.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
Tesamorelin is a modified version of GHRH, the natural signal that tells the pituitary gland to release growth hormone. Its small chemical modification helps make the peptide more stable. Researchers study its effects on normal growth-hormone pulses and on fat stored around the abdominal organs.
Why researchers reach for Tesamorelin
GHRH receptor selectivity
Selectively activates pituitary GHRH receptors.
Visceral fat research
Well-cited in VAT reduction and lipid-profile studies.
Preserves pulsatility
Supports physiological GH pulse patterns in preclinical work.
Key features
- ≥99% HPLC purity
- Modified GHRH(1-44) sequence
- Mass-spec verified
- Cold-chain dispatch
How it works
Receptor engagement
Binds pituitary GHRH receptors to stimulate GH release.
IGF-1 elevation
Downstream IGF-1 rise observed across research cohorts.
Lipolytic signaling
Referenced in VAT and hepatic-lipid endpoints.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Typical reconstitution | 2 mL bacteriostatic water | Yields 2.5 mg/mL (2500 mcg/mL) |
| Reported research range | 1–2 mg/day | Reference only |
Tracking this compound? Registered researchers can log active Tesamorelin protocols in their private Research Log.
Timing in research protocols
Once daily, conventionally at bedtime to align with the nocturnal growth-hormone pulse.
- The phase 3 trial (Falutz et al., NEJM 2007) used 2 mg subcutaneously once daily for 26 weeks, with extension data to 52 weeks.
- Bedtime administration follows GHRH-analogue pharmacology — potentiating the natural night-time growth-hormone pulse — although the trials did not test time of day as a variable.
- Meal relationship was not systematically studied in the registration programme.
- Effects reversed on discontinuation in the trials, so the studied pattern is continuous daily dosing rather than short cycles.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Sequence
- trans-3-hexenoyl-GHRH(1-44)
- Molecular weight
- 5195.8 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 5 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on Tesamorelin. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
